Diagnostic specialist Oncimmune Holdings PLC (AIM:ONC) has inked what it described as a 'go-to-market partnership' with Synexa Life Sciences.
The pair expect to sign “multiple new contracts” for autoantibody profiling, a process aimed at helping improve response and adverse event prediction, patient screening and diagnostic accuracy.
Specifically, Oncimmune’s ImmunoINSIGHTS team will deliver analysis and interpretation of blood samples for Synexa and its clients.
"We welcome this exciting initiative with Synexa Life Sciences, who have recognised the recent progress made by our ImmunoINSIGHTS platform,” said chief executive, Adam Hill.
On Monday Oncimmune said it has signed a commercial collaboration deal with a health company owned by Google’s parent, Alphabet.
The AIM-listed immunodiagnostics firm is teaming up with Verily Life Sciences to assess long Covid data.
Here too it will use autoantibody profiling of patients to see if the markers present early in the infection are associated with persistent symptoms and after-effects and remain present after the initial illness.